Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure

Bone Marrow Transplantation volume 26, pages 685–688 (2000)Cite this article

Abstract

Cyclophosphamide (CPA) is widely used for peripheral blood stem cell mobilization, and a dose adjustment of CPA in the presence of renal failure has not been suggested. However, we describe a myeloma patient with renal failure (serum creatinine 4.2 mg/dl, creatinine clearance 11.2 ml/min) receiving CPA 2 g/m2 for 2 days, who developed unexpectedly severe toxicity, including myopericarditis and prolonged myelosuppression. The serial serum concentrations of CPA metabolites were persistently much higher than those in a myeloma patient with normal renal function. We consider, therefore, that the dose of CPA should be reduced in the presence of severe renal failure when used as high-dose therapy or to mobilize peripheral blood stem cells. Bone Marrow Transplantation (2000) 26, 685–688.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Alexanian R, Dimopoulos M . The treatment of multiple myeloma New Engl J Med 1994 330: 484–489

    Article  CAS  Google Scholar 

  2. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  3. Bramwell V, Calvert RT, Edwards G et al. The disposition of cyclophosphamide in a group of myeloma patients Cancer Chemother Pharmacol 1979 3: 253–259

    Article  CAS  Google Scholar 

  4. Edwards G, Calvert RT, Crowther D et al. Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy Br J Clin Pharmacol 1980 10: 281–285

    Article  CAS  Google Scholar 

  5. Grochow LB, Colvin M . Clinical pharmacokinetics of cyclophosphamide. In: Ames MM, Powis G, Kovach JS (eds) Pharmacokinetics of Anticancer Agents in Humans Elsevier: Amsterdam 1983 pp135–154

    Google Scholar 

  6. Moore MJ . Clinical pharmacokinetics of cyclophosphamide Clin Pharmacokinet 1991 20: 194–208

    Article  CAS  Google Scholar 

  7. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents New Engl J Med 1984 310: 1353–1356

    Article  CAS  Google Scholar 

  8. Klein HO, Wickramanayake PD, Christian E, Coerper C . Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines Cancer 1984 54: (Suppl.6) 1193–1203

    Article  CAS  Google Scholar 

  9. Tochino Y, Iwata T, Takamizawa A, Hamazima Y . Studies on relationship between antitumor activity and metabolism of cyclophosphamide Proc 3rd Symp on Drug Metabolism and Action, Fukuoka, Japan 1971

    Google Scholar 

  10. Alberts DS, van Daalen T . The effect of allopurinol on cyclophosphamide antitumor activity Cancer Res 1976 36: 2790–2794

    CAS  PubMed  Google Scholar 

  11. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency Bone Marrow Transplant 1997 20: 653–656

    Article  CAS  Google Scholar 

  12. Rebibou JM, Caillot D, Casasnovas RO et al. Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure Bone Marrow Transplant 1997 20: 63–65

    Article  CAS  Google Scholar 

  13. Lenhard RE Jr, Oken MM, Barnes JM et al. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma Cancer 1984 53: 1456–1460

    Article  Google Scholar 

  14. Santos GW, Sensenbrenner L, Burke PJ et al. Marrow transplantation in man following cyclophosphamide Transplant Proc 1971 2: 400–404

    Google Scholar 

  15. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy Arch Intern Med 1981 141: 758–763

    Article  CAS  Google Scholar 

  16. Goldberg MA, Antin JH, Guinan EC, Rappeport JM . Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor Blood 1986 68: 1114–1118

    CAS  PubMed  Google Scholar 

  17. Lie AK, Rawling TP, Bayly JL, To LB . Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of haemopoietic growth factor and chemotherapy Br J Haematol 1996 95: 39–44

    Article  CAS  Google Scholar 

  18. Desikan KR, Barlogie B, Tagannath S et al. Comparable engraftment kinetics following peripheral blood stem-cell infusion mobilised with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma J Clin Oncol 1998 16: 1547–1553

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, International Medical Center of Japan, Tokyo, Japan

    R Yamamoto, Y Kanda, T Matsuyama, K Oshima, Y Nannya, M Suguro, A Chizuka, T Hamaki, N Takezako & A Miwa

  2. Stem Cell Transplant Unit, National Cancer Center Hospital, Tokyo, Japan

    R Yamamoto & Y Kanda

  3. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    M Kami

  4. Bone Marrow Transplantation Team, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

    S-i Mori

  5. Department of Cardiology, International Medical Center of Japan, Tokyo, Japan

    T Kojima, K Saito, Y Itaoka & M Kashida

Authors
  1. R Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Matsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Oshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Nannya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Suguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Chizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Hamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Takezako
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Kami
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S-i Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. K Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Y Itaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Kashida
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, R., Kanda, Y., Matsuyama, T. et al. Myopericarditis caused by cyclophosphamide used to mobilize peripheral blood stem cells in a myeloma patient with renal failure. Bone Marrow Transplant 26, 685–688 (2000). https://doi.org/10.1038/sj.bmt.1702592

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702592

Keywords

This article is cited by

Search

Advanced search

Quick links